MedTech Dive July 8, 2024
Carlyle Group could reportedly pay more than $4 billion for Baxter’s Vantive business.
Dive Brief:
- Baxter is considering the sale of its kidney care business to private equity firm Carlyle Group for more than $4 billion, The Wall Street Journal reported on Friday.
- Exclusive negotiations about a potential sale started in late June, the Journal reported, citing unnamed sources. A deal could be announced “in the coming weeks,” although the talks could still fall apart, according to the report. A Baxter spokesperson told MedTech Dive that the company does not comment on market rumors or speculation.
- Baxter announced plans in early 2023 to spin off its kidney care and acute therapies businesses into a separate, publicly traded...
Today's Sponsors
Today's Sponsor